Leerink Partnrs Has Bearish Estimate for Vaxcyte Q3 Earnings

Key Points

• Leerink Partners has lowered its Q3 2025 earnings per share estimate for Vaxcyte to ($1.47), down from a previous estimate of ($1.22).
• Vaxcyte recently reported a Q2 loss of ($1.22) EPS, missing analysts' expectations of ($1.12) EPS by $0.10.
• Vaxcyte's stock currently has an average rating of "Buy" with a consensus price target of $136.50 from multiple analysts.

Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Research analysts at Leerink Partnrs reduced their Q3 2025 earnings per share (EPS) estimates for Vaxcyte in a report issued on Thursday, August 7th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of ($1.47) per share for the quarter, down from their prior forecast of ($1.22). The consensus estimate for Vaxcyte's current full-year earnings is ($4.21) per share. Leerink Partnrs also issued estimates for Vaxcyte's Q4 2025 earnings at ($1.50) EPS, FY2025 earnings at ($5.96) EPS, FY2026 earnings at ($6.58) EPS, FY2027 earnings at ($7.07) EPS, FY2028 earnings at ($6.87) EPS and FY2029 earnings at ($1.69) EPS.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same quarter in the previous year, the firm posted ($1.10) earnings per share.

A number of other research analysts also recently commented on PCVX. Cowen restated a "buy" rating on shares of Vaxcyte in a research note on Thursday. Cantor Fitzgerald assumed coverage on Vaxcyte in a research note on Tuesday, April 22nd. They set an "overweight" rating for the company. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $29.90 on Monday. The business's 50-day moving average price is $34.43 and its two-hundred day moving average price is $48.13. Vaxcyte has a one year low of $27.66 and a one year high of $121.06. The company has a market capitalization of $3.88 billion, a P/E ratio of -7.27 and a beta of 1.21.

Hedge Funds Weigh In On Vaxcyte

Several large investors have recently made changes to their positions in PCVX. National Bank of Canada FI acquired a new position in shares of Vaxcyte during the 4th quarter worth about $41,000. Wells Fargo & Company MN raised its holdings in shares of Vaxcyte by 53.7% in the 4th quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock worth $5,916,000 after buying an additional 25,257 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Vaxcyte by 12.5% during the 4th quarter. Envestnet Asset Management Inc. now owns 55,083 shares of the company's stock worth $4,509,000 after acquiring an additional 6,121 shares during the last quarter. Legal & General Group Plc grew its position in Vaxcyte by 13.4% during the 4th quarter. Legal & General Group Plc now owns 123,664 shares of the company's stock worth $10,123,000 after acquiring an additional 14,574 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Vaxcyte during the 4th quarter worth approximately $4,427,000. Institutional investors and hedge funds own 96.78% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.